Bipolar Radiofrequency Ablation of Refractory Ventricular Arrhythmias: Results from a Multicenter Network.
Options
BORIS DOI
Date of Publication
September 27, 2024
Publication Type
Article
Division/Institute
Author
Futyma, Piotr | |
Sultan, Arian | |
Zarębski, Łukasz | |
Imnadze, Guram | |
Maslova, Vera | |
Bordignon, Stefano | |
Kousta, Maria | |
Knecht, Sven | |
Pavlović, Nikola | |
Peichl, Petr | |
Lian, Evgeny | |
Scherr, Daniel | |
Pfeffer, Michael | |
Moskal, Paweł | |
Gabriel, Cismaru | |
Antolič, Bor | |
Wałek, Paweł | |
Chen, Shaojie | |
Martinek, Martin | |
Kollias, Georgios | |
Derndorfer, Michael | |
Seidl, Sebastian | |
Schmidt, Boris | |
Lüker, Jakob | |
Steven, Daniel | |
Sommer, Philipp | |
Jastrzębski, Marek | |
Kautzner, Josef | |
Sticherling, Christian | |
Pürerfellner, Helmut | |
Enriquez, Andres | |
Wörmann, Jonas | |
Chun, Julian K R |
Series
EP Europace
ISSN or ISBN (if monograph)
1099-5129
Publisher
Oxford University Press
Language
English
Publisher DOI
PubMed ID
39331050
Description
Background
Advanced ablation strategies are needed to treat ventricular tachycardia (VT) and premature ventricular contractions (PVC) refractory to standard unipolar radiofrequency ablation (Uni-RFA). Bipolar radiofrequency catheter ablation (Bi-RFA) has emerged as a treatment option for refractory VT, PVC. Multicenter registry data on the use of Bi-RFA in the setting of refractory VT and PVC are lacking.Purpose
The aim of this Bi-RFA registry is to determine its real-world safety, feasibility, and efficacy in patients with refractory VT/PVC.Methods
Consecutive patients undergoing Bi-RFA at sixteen European centers for recurring VT/PVC after at least one standard Uni-RFA were included. Second ablation catheter was used instead of a dispersive patch and was positioned at the opposite site of the ablation target.Results
Between March 2021 and August 2024, ninety-one patients underwent 94 Bi-RFA procedures (74 males, age 62±13, prior Uni-RFA range 1-8). Indications were recurrence of PVC (n=56), VT (n=20), electrical storm (n=13), or PVC-triggered ventricular fibrillation (n=2). Procedural time was 160±73min, Bi-RFA time 426±286s, mean Uni-RFA time 819±697s. Elimination of clinical VT/PVC was achieved in 67 (74%) patients, suppression of VT/PVC in a further 10 (11%) patients. In the remaining 14 patients (15%) no effect on VT/PVC was observed. Three major complications occurred: coronary artery occlusion, AV block and arteriovenous fistula. Follow-up lasted 7±8 months. Nineteen (61%) remained VT-free. ≥80% PVC burden reduction was achieved in 45 (78%).Conclusions
This real-world registry data indicates that Bi-RFA appears safe, is feasible, and effective in the majority of patients with VT/PVC.
Advanced ablation strategies are needed to treat ventricular tachycardia (VT) and premature ventricular contractions (PVC) refractory to standard unipolar radiofrequency ablation (Uni-RFA). Bipolar radiofrequency catheter ablation (Bi-RFA) has emerged as a treatment option for refractory VT, PVC. Multicenter registry data on the use of Bi-RFA in the setting of refractory VT and PVC are lacking.Purpose
The aim of this Bi-RFA registry is to determine its real-world safety, feasibility, and efficacy in patients with refractory VT/PVC.Methods
Consecutive patients undergoing Bi-RFA at sixteen European centers for recurring VT/PVC after at least one standard Uni-RFA were included. Second ablation catheter was used instead of a dispersive patch and was positioned at the opposite site of the ablation target.Results
Between March 2021 and August 2024, ninety-one patients underwent 94 Bi-RFA procedures (74 males, age 62±13, prior Uni-RFA range 1-8). Indications were recurrence of PVC (n=56), VT (n=20), electrical storm (n=13), or PVC-triggered ventricular fibrillation (n=2). Procedural time was 160±73min, Bi-RFA time 426±286s, mean Uni-RFA time 819±697s. Elimination of clinical VT/PVC was achieved in 67 (74%) patients, suppression of VT/PVC in a further 10 (11%) patients. In the remaining 14 patients (15%) no effect on VT/PVC was observed. Three major complications occurred: coronary artery occlusion, AV block and arteriovenous fistula. Follow-up lasted 7±8 months. Nineteen (61%) remained VT-free. ≥80% PVC burden reduction was achieved in 45 (78%).Conclusions
This real-world registry data indicates that Bi-RFA appears safe, is feasible, and effective in the majority of patients with VT/PVC.
File(s)
File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
---|---|---|---|---|---|---|---|
euae248.pdf | text | Adobe PDF | 3.02 MB | published |